PDCD1 and neoplasm: These results are in line with recent reports mentioning that PD-L1 expression and TMB have non-overlapping effects on the response rate to PD-1/PD-L1 inhibitors and can thus, be used to categorize the immunologic subtypes of different tumor types (76, 96).